Department of Perioperative Medicine, CHU Clermont-Ferrand, Clermont-Ferrand, France; GReD, Université Clermont Auvergne, CNRS, INSERM, Clermont-Ferrand, France.
GReD, Université Clermont Auvergne, CNRS, INSERM, Clermont-Ferrand, France.
Anaesth Crit Care Pain Med. 2022 Oct;41(5):101133. doi: 10.1016/j.accpm.2022.101133. Epub 2022 Jul 27.
Inhaled sedation with halogenated agents, such as isoflurane or sevoflurane, is now feasible in intensive care unit (ICU) patients through dedicated vaporisers and scavenging systems. Such a sedation strategy requires specific equipment and adequate training of ICU teams. Isoflurane and sevoflurane have ideal pharmacological properties that allow efficient, well-tolerated, and titratable light-to-deep sedation. In addition to their function as sedative agents, these molecules may have clinical benefits that could be especially relevant to ICU patients. Our goal was to summarise the pharmacological basis and practical aspects of inhaled ICU sedation, review the available evidence supporting inhaled sedation as a viable alternative to intravenous sedation, and discuss the remaining areas of uncertainty and future perspectives of development.
通过专用蒸发器和清除系统，现在可以在重症监护病房（ICU）患者中使用卤代制剂（如异氟烷或七氟烷）进行吸入镇静。这种镇静策略需要特定的设备和 ICU 团队的充分培训。异氟烷和七氟烷具有理想的药理学特性，可实现高效、耐受良好且可滴定的浅至深镇静。除了作为镇静剂的作用外，这些分子可能具有临床益处，这可能对 ICU 患者尤其重要。我们的目标是总结 ICU 吸入镇静的药理学基础和实际方面，回顾支持吸入镇静作为静脉镇静可行替代方案的现有证据，并讨论尚存的不确定性领域和未来的发展前景。
